Fjarde AP Fonden Fourth Swedish National Pension Fund cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,776 shares of the life sciences company’s stock after selling 1,893 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Illumina were worth $14,233,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Kaizen Advisory LLC lifted its position in shares of Illumina by 161.0% in the 2nd quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock valued at $103,000 after acquiring an additional 227 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its position in shares of Illumina by 2,670.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after acquiring an additional 9,345 shares in the last quarter. Sun Life Financial INC lifted its position in shares of Illumina by 152.5% in the 2nd quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after acquiring an additional 241 shares in the last quarter. Highstreet Asset Management Inc. purchased a new stake in shares of Illumina in the 3rd quarter valued at approximately $112,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Illumina by 3,192.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock valued at $120,000 after acquiring an additional 415 shares in the last quarter. 91.60% of the stock is owned by institutional investors and hedge funds.

In other Illumina news, insider Francis A. Desouza sold 2,100 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $369.61, for a total value of $776,181.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction dated Wednesday, November 14th. The stock was sold at an average price of $312.50, for a total transaction of $1,031,250.00. Following the transaction, the director now directly owns 376,710 shares of the company’s stock, valued at $117,721,875. The disclosure for this sale can be found here. Insiders sold a total of 66,764 shares of company stock worth $22,060,881 over the last quarter. 0.54% of the stock is currently owned by company insiders.

Several equities research analysts recently commented on ILMN shares. Bank of America upped their price target on shares of Illumina from $345.00 to $370.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. BidaskClub downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Deutsche Bank upped their price target on shares of Illumina from $280.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Citigroup increased their target price on shares of Illumina from $330.00 to $345.00 and gave the stock a “buy” rating in a research report on Tuesday, July 31st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $340.00 target price (up previously from $330.00) on shares of Illumina in a research report on Friday, July 27th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $330.94.

Shares of ILMN opened at $301.59 on Tuesday. Illumina, Inc. has a 12 month low of $207.51 and a 12 month high of $372.61. The firm has a market cap of $47.03 billion, a PE ratio of 75.40, a price-to-earnings-growth ratio of 2.37 and a beta of 1.07. The company has a current ratio of 2.46, a quick ratio of 2.24 and a debt-to-equity ratio of 0.24.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.26. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The business had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. During the same period last year, the business posted $1.11 EPS. Illumina’s revenue was up 19.5% compared to the same quarter last year. Equities research analysts forecast that Illumina, Inc. will post 5.75 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2018/11/20/fjarde-ap-fonden-fourth-swedish-national-pension-fund-sells-1893-shares-of-illumina-inc-ilmn.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Read More: Understanding debt-to-equity ratio in fundamental analysis

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.